Gene · 79679
NIH grants878
NIH grants whose papers are about the gene, through NIH's grant-paper links.
261 to 280 of 878
Download this page as JSON| Grant | Title | VTCN1 papers | Newest fiscal year |
|---|---|---|---|
| U2CCA233280 | Omic and Multidimensional Spatial Atlas of Metastatic Breast Cancer | 1 | 2023 |
| UL1TR001420 | Wake Forest Clinical and Translational Science Award | 1 | 2023 |
| T32GM007288 | Medical Scientist Training Program | 7 | 2022 |
| P50CA062924 | SPORE in Gastrointestinal Cancers | 2 | 2022 |
| P50CA140388 | Administrative Supplement to MD Anderson Cancer Center Prostate Cancer SPORE | 2 | 2022 |
| R01DE028172 | T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer | 2 | 2022 |
| R01HL147565 | IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activation | 2 | 2022 |
| DP1CA238296 | Forecasting tumor evolution: can the past reveal the future? | 1 | 2022 |
| F30CA239313 | Quantifying patient-specific tumor evolutionary dynamics and resistance mechanisms in HER2-positive breast cancers treated with targeted therapy | 1 | 2022 |
| F31CA257276 | Dissecting the roles of a novel immune-checkpoint receptor complex in driving T cell dysfunction in cancers | 1 | 2022 |
| I01BX003296 | Elucidation of MLK3 Signaling in Hepatocellular Carcinoma | 1 | 2022 |
| K99CA248611 | Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma | 1 | 2022 |
| K99CA259329 | Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis | 1 | 2022 |
| R01CA155169 | Understanding Resistance to Next Generation Antiandrogens | 1 | 2022 |
| R01CA204856 | Drug repurposing in breast cancer | 1 | 2022 |
| R01CA223150 | In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices | 1 | 2022 |
| R01CA223804 | Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer | 1 | 2022 |
| R01CA229784 | Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma | 1 | 2022 |
| R01CA234018 | Regulators of Cancer Immunotherapy Response | 1 | 2022 |
| R01CA236615 | Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/79679/grants?page=14